| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2010 | WO2010011302A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 01/28/2010 | WO2010011296A2 Deacetylase inhibitors and uses thereof |
| 01/28/2010 | WO2010011289A2 Parenteral and oral formulations of benzimidazoles |
| 01/28/2010 | WO2010011154A1 Methods for identifying biomarkers, therapies and compounds suitable for the treatment of depression and schizophrenia and pharmaceutical compositions thereof and development of drugs targeting a newly discovered cns arachidonic acid pathway of anhedonia |
| 01/28/2010 | WO2010011147A1 Indole compounds |
| 01/28/2010 | WO2010011119A1 Ophthalmic solution for corneal enlargement |
| 01/28/2010 | WO2010011117A2 Ndga-containing composition for the suppression of transglutaminase |
| 01/28/2010 | WO2010011111A2 Composition for control of aging and / or extension of life, containing dapsone as active ingredient |
| 01/28/2010 | WO2010011093A2 Composition for the treatment of skin flaps, comprising curcumin as an active ingredient |
| 01/28/2010 | WO2010010980A1 Composition containing microrna-21 inhibitor for enhancing radiation sensitivity |
| 01/28/2010 | WO2010010948A1 Protection against norovirus infection or removal of norovirus by using substance associated with blood type |
| 01/28/2010 | WO2010010939A1 Prophylactic or therapeutic agent for age-related macular degeneration |
| 01/28/2010 | WO2010010935A1 Optically active heterocyclidene-n-arylacetamide derivative |
| 01/28/2010 | WO2010010934A1 Heterocyclidene derivative having p-substituted arylacetamide |
| 01/28/2010 | WO2010010933A1 Heterocyclidene-n-(3,4-dihydro-2(1h)-quinazolin-5-yl) acetamide derivative |
| 01/28/2010 | WO2010010909A1 Therapeutic agent for chronic renal failure |
| 01/28/2010 | WO2010010908A1 Therapeutic agent for migraine |
| 01/28/2010 | WO2010010797A1 Pharmaceutical composition comprising dyrk-inhibiting compound |
| 01/28/2010 | WO2010010715A1 Stable aqueous solution composition containing sulfonamide compound |
| 01/28/2010 | WO2010010702A1 Prophylactic or therapeutic agent for axial myopia |
| 01/28/2010 | WO2010010689A1 Liquid preparation for contact lenses |
| 01/28/2010 | WO2010010579A1 Multiple unit dosage form of niacin |
| 01/28/2010 | WO2010010531A2 Composition for controlling increase in blood glucose |
| 01/28/2010 | WO2010010470A2 Methods of administering topical antifungal formulations for the treatment of fungal infections |
| 01/28/2010 | WO2010010464A2 Fesoterodine substantially free of dehydroxy impurity |
| 01/28/2010 | WO2010010458A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 01/28/2010 | WO2010010454A2 Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
| 01/28/2010 | WO2010010431A1 Self-nano-emulsifying curcuminoids composition with enhanced bioavailability |
| 01/28/2010 | WO2010010380A1 Potassium ion channel modulators & uses thereof |
| 01/28/2010 | WO2010010367A1 Solid pharmaceutical composition comprising exemestane |
| 01/28/2010 | WO2010010365A1 Polyunsaturated fatty acids for improving vision |
| 01/28/2010 | WO2010010347A1 Pyrrolobenzodiazepines |
| 01/28/2010 | WO2010010346A2 Topical compositions for use during tooth eruption |
| 01/28/2010 | WO2010010288A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 01/28/2010 | WO2010010191A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| 01/28/2010 | WO2010010190A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | WO2010010189A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | WO2010010188A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| 01/28/2010 | WO2010010187A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | WO2010010186A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | WO2010010184A1 [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| 01/28/2010 | WO2010010178A1 The tuberculosis rv2707c protein, compositions and uses thereof |
| 01/28/2010 | WO2010010174A1 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| 01/28/2010 | WO2010010168A1 Transdermal pharmaceutical compositions comprising danazol |
| 01/28/2010 | WO2010010154A1 3,4-diarylpyrazoles as protein kinase inhibitors |
| 01/28/2010 | WO2010010149A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 01/28/2010 | WO2010010148A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 01/28/2010 | WO2010010147A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 01/28/2010 | WO2010010141A1 Pramipexole for treating cardiomyopathy |
| 01/28/2010 | WO2010010138A1 Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease |
| 01/28/2010 | WO2010010136A1 Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease |
| 01/28/2010 | WO2010010133A1 2-thia-1,3-diazaspirocyclic-substituted phenylacetamides as glt1 mediators for neurological diseases |
| 01/28/2010 | WO2010010127A1 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 01/28/2010 | WO2010010106A1 Aminophosphinic derivatives that can be used in the treatment of pain |
| 01/28/2010 | WO2010010101A1 Isosorbide nitrates having vasodilating activity |
| 01/28/2010 | WO2010010080A1 Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| 01/28/2010 | WO2010010056A1 Process for the preparation of esomeprazole magnesium in a stable form |
| 01/28/2010 | WO2010010017A1 Heterocyclic antiviral compounds |
| 01/28/2010 | WO2010010014A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/28/2010 | WO2010009985A2 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 01/28/2010 | WO2010009967A1 Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
| 01/28/2010 | WO2010009961A1 Pharmaceutical formulation for treating the upper digestive tract |
| 01/28/2010 | WO2010009900A1 Paliperidone composition comprising solid matrix particles |
| 01/28/2010 | WO2010009891A1 Pharmaceutical dosage forms for time-specific drug delivery |
| 01/28/2010 | WO2010009845A1 Sulfone substituted quinazoline derivatives as immune-modulators for the treatment of inflammatory and allergic diseases |
| 01/28/2010 | WO2010009828A1 Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| 01/28/2010 | WO2010009814A1 5-[ (3,3,3-trifluoro-2-hydroxy-1-arylpropyl) amino]-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| 01/28/2010 | WO2010009775A1 Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| 01/28/2010 | WO2010009745A1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
| 01/28/2010 | WO2010009739A1 Copper(i)chloride complex of nicotinic acid and pharmaceutical compositions containing the same. |
| 01/28/2010 | WO2010009619A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 01/28/2010 | WO2010009618A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 01/28/2010 | WO2010009578A1 Use of tyrosinase inhibitor as skin whitening compound |
| 01/28/2010 | WO2010009572A1 New low side effect pharmaceutical composition containing isoniazid |
| 01/28/2010 | WO2010009535A1 A method for inhibiting poxvirus infection and pathogenesis using the alkaloid berberine |
| 01/28/2010 | WO2010009508A1 Antiparasitic compounds |
| 01/28/2010 | WO2010009492A1 ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 μM TO ABOUT 10 μM |
| 01/28/2010 | WO2010009487A1 Chlorophyll catabolites |
| 01/28/2010 | WO2009152462A3 Method of regulating cell growth using a proteasome inhibitor |
| 01/28/2010 | WO2009151845A9 Compounds for rho kinase inhibition and for improving learning and memory |
| 01/28/2010 | WO2009148961A3 Drugs to prevent hpv infection |
| 01/28/2010 | WO2009148552A3 Methods and compositions for treating disease |
| 01/28/2010 | WO2009147441A3 Novel treatments |
| 01/28/2010 | WO2009147075A3 Pharmaceutical compositions containing a crystalline form of posaconazole |
| 01/28/2010 | WO2009146144A3 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator |
| 01/28/2010 | WO2009145357A8 Benzo [1, 4] diazepines substituted at the 1-position by a ring, for use as antidepressants |
| 01/28/2010 | WO2009140665A3 Identification of a molecular signature for antipsychotics and serms |
| 01/28/2010 | WO2009140089A3 Sulfone compounds which modulate the cb2 receptor |
| 01/28/2010 | WO2009138707A9 Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| 01/28/2010 | WO2009136396A3 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 01/28/2010 | WO2009134856A3 Pharmaceutical gallium compounds, composition and methods of preparation |
| 01/28/2010 | WO2009132454A8 Di-t-butylphenyl piperazines as calcium channel blockers |
| 01/28/2010 | WO2009132452A8 Diaryl-cyclylalkyl derivatives as calcium channel blockers |
| 01/28/2010 | WO2009129465A3 Compositions and methods for inhibiting expression of xbp-1 gene |
| 01/28/2010 | WO2009129456A3 Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| 01/28/2010 | WO2009129439A3 Medical devices and methods including polymers having biologically active agents therein |
| 01/28/2010 | WO2009129432A3 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| 01/28/2010 | WO2009129149A4 Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| 01/28/2010 | WO2009129148A3 Methods and compositions for treating intervertebral disc herniations |
| 01/28/2010 | WO2009126933A3 Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |